Get full details of report at: http://www.reportsandintelligence.com/companion-diagnostic-technologies-market Companion diagnostics are a form of in-vitro diagnostics which provide data about the therapeutic reactions of patients for a particular treatment. Companion diagnostics market is still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020. The global companion diagnostic market is divided on the basis of technology, geography and indication (North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is growing rapidly. Factors that are contributing towards the growth of market are invention of biomarkers and co-development of drug and corresponding diagnostic. However, high cost of drug development would deter the market growth. Opportunities for the market would be in the development of companion diagnostics for hereditary conditions numerous central nervous system conditions.

1. Global Companion Diagnostic Technologies Market (Indication
and Geography) - Size, Share, Global Trends, Company
Profiles, Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 - 2020
Published: June 2014
Pages: 107
Contact Us: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Mail us: sales@reportsandintelligence.com
Detailed report at:
http://www.reportsandintelligence.com/companion-diagnostic-
technologies-market

2. Companion diagnostics are a form of in-vitro diagnostics which provide data about the
therapeutic reactions of patients for a particular treatment. Companion diagnostics market is
still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market
value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020. The global
companion diagnostic market is divided on the basis of technology, geography and indication
(North America, Europe, Asia Pacific and LAMEA). Geographically, LAMEA is growing rapidly.
Factors that are contributing towards the growth of market are invention of biomarkers and co-
development of drug and corresponding diagnostic. However, high cost of drug development
would deter the market growth. Opportunities for the market would be in the development of
companion diagnostics for hereditary conditions numerous central nervous system conditions.
Companion Diagnostics Indication Market Analysis
Companion diagnostics is divided based on its utilization for indication, for example, oncology,
cardiovascular conditions, focal sensory system evidences, irritation and virology. Oncology is
the maximum revenue generating segment, as most of the CD technology has been developed
to invent oncology biomarkers. Increasing research and development of targeted drugs is the
main driving factor for this market.
Companion Diagnostics Technology Market Analysis
The report segments the companion diagnostics technology market on the basis of
Immunohistochemistry and Molecular diagnostics. Atomic diagnostics would be the quickest
developing and the maximum income generator, basically because of the utilization of
procedures, for example, constant PCR, In Situ Hybridization and cutting edge sequencing.
Different components helping the development are mechanical progressions in atomic
diagnostics, which has brought about expanded precision and exactness and likewise decreased
expense of testing through these methods.
Companion Diagnostics Geography Market Analysis
Companion Diagnostics market has been sectioned geographically into North America, Europe,
Asia Pacific and LAMEA. North America has the significant piece of the pie of 43.97%, followed
by Europe, which represented something like 38% of the general CD market in 2013. North

3. America and Europe together represented in excess of 82% in the worldwide CD market in 2013
and they would keep on being the significant markets until 2020..
Competitive Analysis
A detailed research of key players has demonstrated that most of the companies in this
business sector are concentrating on coordinated efforts with drug organizations. The top
players included in the report are Dako (Agilent Technologies), Qiagen, Roche, Abbott
Laboratories, Inc., Ventana Medical Systems, biomerieux, Myriad Genetics, Inc., Resonance
Health Ltd., Leica Microsystems, and Life Technologies.
High Level Analysis
The report is concentrating on the patterns in diagnosis and technology of various indications,
which are driving the development of the companion diagnostics market. Research of the
business is focused around others five force model that shows the negotiating power of the
suppliers is high, as the items delivered are very distinguished. The risk of new entrants is low
as noteworthy innovative work is needed for creating diagnostic tests. Further, the cash flow
required is also high. These components make it difficult for new organizations to enter the
business. The risk of substitutes is low in this business sector as companion diagnostics are
created for particular biomarkers and the products are highly distinguished. Since it is an
emerging market with few companies, the completion is not high. Government regulations are
favoring utilization of companion diagnostics for the deciding a specific treatment.
Organizations are concentrating on joint efforts with pharmaceutical organizations as a key
procedure to further bolster the market growth.
Reason for doing the study
Companion diagnostics are a critical part of the personalized treatment approach and are
fundamental to identify therapeutic response to a specific medication. Rising cases of diseases
and healthcare awareness would increase the market scope.

4. KEY BENEFITS
 In-depth analysis of the companion diagnostic market by technology and indications
give a clear idea of the scope of this market
 Analysis of the market by geography would help in making region specific plans
 Estimations for period of 2013 to 2020 have been given, taking into consideration the
current market scenario and future trends, which would give a clearer picture of the
potential of the market
 Porter’s five force model and SWOT analysis would help in a deeper understanding of
the market and help in making strategic decisions
 Top factors impacting the market would help in making decisions for business
development
KEY DELIVERABLES
MARKET BY INDICATIONS
 Oncology
 Cardiovascular
 Central Nervous System
 Auto immune & Inflammation
 Virology
 Others
MARKET BY TECHNOLOGY
 Immunohistochemistry
 Molecular diagnostics
o In situ Hybridization
 FISH
 CISH
o Real time PCR
o Gene Sequencing
MARKET BY GEOGRAPHY
 North America
 Europe
 Asia Pacific
 LAMEA

5. Table of Content
CHAPTER 1. INTRODUCTION
1.1 Reportdescription
1.2 Keymarketsegments
1.3 Researchmethodology
1.3.1 Secondaryresearch
1.3.2 Primaryresearch
1.3.3 Analysttoolsandmodels
CHAPTER 2. EXECUTIVE SUMMARY
CHAPTER 3. MARKETOVERVIEW
3.1 MarketDefinitionand Scope
3.2 CompanionDiagnosticsforMetabolicDiseases
3.3 Novel trendsandtechnologiesincompaniondiagnosticsassaydevelopment
3.4 Companiondiagnosticsasa newtrendinpersonalizedmedicine
3.5 Biomarkersmarketasbasisforthe companiondiagnosticsindustry
3.6 KeyFindings
3.6.1 Top FactorsImpactingThe CompanionDiagnosticMarket
3.6.2 Top WinningStrategies
3.7 Porter’sfive forcesanalysis
3.7.1 Highswitchingcostleadstohigherbargainingpowerof suppliers
3.7.2 Highlydifferentiatedproductsleadstolowerbargainingpowerof buyers
3.7.3 Specificityof diagnosticslowersthe threatof substitutes
3.7.4 Highercapital investmentleadstolesserthreatof entrants
3.7.5 Fewcompetitorsleads tolowcompetitionamongplayers
3.8 GovernmentRegulations
3.8.1 FDA regulations
3.8.2 Europe
3.8.3 Japan
3.8.4 China
3.9 Value ChainAnalysis
3.10 Case Study
3.11 Drivers
3.11.1 Increasedpopularityof Personalizedmedicine
3.11.2 Increasingcasesof adverse drugreactions(ADRs)
3.11.3 Increase inthe Discoveryof Biomarkersasdrug targets.
3.11.4 Risingsuccessof co-developmentdrugsspeedilyapprovedbythe FDA
3.11.5 Technological advancements
3.11.6 Risingincidencesof diseases
3.12 Restraints
3.12.1 High Costinresearchand developmentof drugs

6. 3.12.1.1 Economicand scientificobstacles
3.12.2 Opportunities
3.12.2.1 Opportunitiesintreatmentof neurodegenerative diseases
3.12.2.2 Companiondiagnosticsforhereditarymutations
CHAPTER 4. GLOBAL COMPANION DIAGNOSTIC MARKETBY INDICATIONS
4.1 Oncology
4.1.1 Companiondiagnosticsoncologymarketbygeography,
4.1.2 BreastCancer
4.1.2.1 companiondiagnosticsbreastcancermarketbygeography
4.1.3 LungCancer
4.1.3.1 companiondiagnosticslungcancermarketbygeography
4.1.4 Colorectal Cancer
4.1.4.1 companiondiagnosticsColorectal Cancermarketbygeography
4.1.5 Gastric cancer
4.1.5.1 companiondiagnosticsGastricCancermarketby geography
4.1.6 Melanomas
4.1.6.1 companiondiagnosticsMelanomamarketbygeography
4.2 InflammationandAutoimmune diseases
4.2.1 Companiondiagnosticsinflammationmarketbygeography
4.3 Companiondiagnosticsincardiovasculardiseases
4.3.1 Companiondiagnosticstestsforwarfarin
4.3.2 Companiondiagnosticscardiovascularmarketbygeography
4.4 CompaniondiagnosticsinCNSdisorders
4.4.1 CompaniondiagnosticsCNSmarketbygeography
4.5 Companiondiagnosticstestsinvirologydiseases
4.5.1 Companiondiagnosticsvirologymarketbygeography
4.6 Others
4.6.1 Companiondiagnosticsothersmarketbygeography
CHAPTER 5. GLOBAL COMPANION DIAGNOSTIC MARKETBY TECHNOLOGY
5.1 Companiondiagnosticstechnologymarketbygeography
5.2 Immunohistochemistry
5.2.1 CompaniondiagnosticsImmmunohistochemistrymarketbygeography
5.3 MolecularDiagnostics
5.3.1 Companiondiagnosticsmoleculardiagnosticsmarketbytypes
5.3.2 CompaniondiagnosticsMolecularDiagnosticsmarketbygeography
5.3.3 In-situHybridization
5.3.3.1 FluorescentIn-situHybridization(FISH)
5.3.3.2 CISH(ChromogenicIn-SituHybridization)
5.3.3.3 CompaniondiagnosticsInsituHybridizationmarketbygeography
5.3.4 Real Time PCR
5.3.4.1 CompaniondiagnosticsRTPCRmarketby geography
5.3.5 Gene Sequencing
5.3.5.1 CompaniondiagnosticsSequencingmarketbygeography

7. 5.3.6 Others
5.3.6.1 Othersmolecularcompaniondiagnosticsmarketbygeography
CHAPTER 6. GLOBAL COMPANION DIAGNOSTICS BY GEOGRAPHY
6.1 NorthAmerica
6.1.1 CompaniondiagnosticsNorthAmericamarketbyindication
6.2 Europe
6.2.1 CompaniondiagnosticsEurope marketbyindication
6.3 AsiaPacific
6.3.1 CompaniondiagnosticsAsiaPacificmarketbyindication
6.4 RoW
6.4.1 CompaniondiagnosticsRoWmarketbyindication
CHAPTER 7. COMPANY PROFILES
7.1 Qiagen
7.1.1 CompanyOverview:
7.1.2 CompanySnapshot
7.1.3 BusinessPerformance
7.1.4 Strategymove anddevelopment
7.1.4.1 Principal strategiesCollaborations
7.1.4.2 SecondaryStrategiesApproval
7.1.5 SWOT Analysisof Qiagen
7.2 Dako(AgilentTechnologies)
7.2.1 CompanyOverview
7.2.2 CompanySnapshot
7.2.3 BusinessPerformance
7.2.4 StrategicMovesandDevelopment
7.2.4.1 Principal strategiesCollaboration
7.2.4.2 SecondaryStrategiesApproval
7.2.5 SWOT Analysisof Dako
7.3 Roche
7.3.1 Companyoverview
7.3.2 CompanySnapshot
7.3.3 BusinessPerformance
7.3.4 Strategiesmove anddevelopment
7.3.5 SWOT analysisof Roche
7.4 AbbottLaboratories,Inc.
7.4.1 CompanyOverview
7.4.2 CompanySnapshot
7.4.3 BusinessPerformance
7.4.4 Principal StrategiesCollaboration
7.4.5 SWOT Analysisof Abbot
7.5 BioMerieux
7.5.1 CompanyOverview
7.5.2 Companysnapshot:
7.5.3 BusinessPerformance

8. 7.5.4 StrategiesanddevelopmentApproval
7.5.5 SWOT Analysisof BioMerieux,
7.6 VentanaMedical Systems
7.6.1 CompanyProfile
7.6.2 CompanySnapshot
7.6.3 BusinessPerformance
7.6.4 Strategiesanddevelopment
7.6.5 SWOT Analysisof Ventana
7.7 MyriadGenetics,Inc.
7.7.1 CompanyOverview
7.7.2 Companysnapshot
7.7.3 BusinessPerformance
7.7.4 Strategies and development
7.7.5 SWOT Analysisof Myraid
7.8 Resonance HealthLtd
7.8.1 CompanyOverview
7.8.2 CompanySnapshot
7.8.3 Strategiesmove anddevelopment
7.8.4 SWOT Analysisof Ferriscan
7.9 LeicaMicrosystems
7.9.1 Companyoverview
7.9.2 CompanySnapshot
7.9.3 Strategiesmove andDevelopment
7.9.4 SWOT Analysisof LeicaMicrosystems
7.10 Life Technologies
7.10.1 CompanyOverview
7.10.2 CompanySnapshot
7.10.3 Businessperformance
7.10.4 Strategiesmove andDevelopment
7.10.5 SWOT Analysisof Life Technologies
LIST OF TABLES
TABLE 1 GLOBAL COMPANION DIAGNOSTICSMARKETBY INDICATION,2013-2020 ($MILLION)
TABLE 2 COMPANION DIAGNOSTICSINDICATION MARKETBYGEOGRAPHY, 2013-2020 ($MILLION)
TABLE 3 GLOBAL COMPANION DIAGNOSTICSMARKETBY ONCOLOGY,2013-2020, ($MILLION)
TABLE 4 COMPANION DIAGNOSTICSONCOLOGYMARKETBY GEOGRAPHY, 2013-2020, ($MILLION)
TABLE 5 COMPANION DIAGNOSTICSBREASTCANCERMARKETBY GEOGRAPHY,2013-2020 ($MILLION)
TABLE 6 COMPANION DIAGNOSTICSLUNGCANCERMARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 7 COMPANION DIAGNOSTICSCOLORECTALCANCERMARKETBY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 8 COMPANION DIAGNOSTICSGASTRICCANCERMARKETBY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 9 COMPANION DIAGNOSTICSMELANOMA MARKETBY GEOGRAPHY,2013-2020 ($MILLION)
TABLE 10 COMPANION DIAGNOSTICSINFLAMMATION MARKETBY GEOGRAPHY,2013-2020 ($MILLION)
TABLE 11 COMPANION DIAGNOSTICSCARDIOVASCULARMARKETBY GEOGRAPHY, 2013-2020
($MILLION)

9. TABLE 12 COMPANION DIAGNOSTICSCNSMARKETBY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 13 COMPANION DIAGNOSTICSVIROLOGYMARKETBY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 14 COMPANION DIAGNOSTICSOTHERSMARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 15 COMPANION DIAGNOSTICSTECHNOLOGYMARKET BY TECHNOLOGY 2013-2020 ($MILLION)
TABLE 16 COMPANION DIAGNOSTICSTECHNOLOGYMARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 17 COMPANION DIAGNOSTICSIMMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 18 COMPANION DIAGNOSTICSMOLECULARDIAGNOSTICSMARKET BY TYPES 2013-2020
($MILLION)
TABLE 19 COMPANION DIAGNOSTICSMOLECULARDIAGNOSTICSMARKET BY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 20 COMPANION DIAGNOSTICSIN SITUHYBRIDIZATION MARKET BY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 21 COMPANION DIAGNOSTICSRTPCR MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 22 COMPANION DIAGNOSTICSSEQUENCINGMARKETBY GEOGRAPHY,2013-2020 ($MILLION)
TABLE 23 OTHERS MOLECULAR COMPANION DIAGNOSTICSMARKETBY GEOGRAPHY, 2013-2020
($MILLION)
TABLE 24 COMPANION DIAGNOSTICSOTHERSMARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25 COMPANION DIAGNOSTICSNORTHAMERICA MARKET, 2013-2020 ($MILLION)
TABLE 26 COMPANION DIAGNOSTICSEUROPEMARKET, 2013-2020 ($MILLION)
TABLE 27 COMPANION DIAGNOSTICSASIA-PACIFICMARKET,2013-2020 ($MILLION)
TABLE 28 COMPANION DIAGNOSTICSROWMARKET,2013-2020 ($MILLION)
TABLE 29 QIAGEN SNAPSHOT
TABLE 30 DAKO COMPANYSNAPSHOT
TABLE 31 ROCHE COMPANYSNAPSHOT
TABLE 32 ABBOTT COMPANYSNAPSHOT
TABLE 33 BIOMERIEUX COMPANYSNAPSHOT
TABLE 34 VENTANA COMPANYSNAPSHOT
TABLE 35 MYRIAD COMPANYSNAPSHOT
TABLE 36 RESONANCECOMPANYSNAPSHOT
TABLE 37 LEICA COMPANYSNAPSHOT
TABLE 38 LIFE TECHNOLOGIESCOMPANYSNAPSHOT
LIST OF FIGURES
FIG.1 COMPANION DIAGNOSTICSASA NEWTREND IN PERSONALIZEDMEDICINE
FIG.2 EFFECTIVENESSOFCOMPANION DIAGNOSTICSIN LUNGCANCERPATIENTS
FIG.3 LIST BIOMARKERSAND THE COMPANION DIAGNOSTICSFORVARIOUSDISEASES
FIG.4 TOP FACTORSIMPACTINGTHE COMPANION DIAGNOSTICMARKET
FIG.5 TOP WINNINGSTRATEGIES
FIG.6 VALUE CHAIN ANALYSIS
FIG.7 FINANCIALREVENUESBY BUSINESSUNITS (2013)
FIG.8 FINANCIALREVENUESBY GEOGRAPHY(2013)
FIG.9 SWOT ANALYSISOFQIAGEN
FIG.10 FINANCIALREVENUEOF DAKO,BY SEGMENT (2012)
FIG.11 SWOT ANALYSISOFDAKO
FIG.12 FINANCIALREVENUEOF DAKO,BY SEGMENT

10. FIG.13 FINANCIALREVENUEOF DAKO,BY GEOGRAPHY
FIG.14 SWOT ANALYSISOFROCHE
FIG.15 REVENUE BY BUSINESSSEGMENTS
FIG.16 REVENUE BY GEOGRAPHY
FIG.17 SWOT ANALYSISOFABBOTT
FIG.18 FINANCIALREVENUESBY GEOGRAPHY
FIG.19 FINANCIALREVENUESBY TECHNOLOGY
FIG.20 SWOT ANALYSISOFBIOMERIEUX
FIG.21 SWOT ANALYSISOFVENTANA
FIG.22 REVENUE BY DIAGNOSTICTYPE
FIG.23 SWOT ANALYSISOFMYRAID
FIG.24 SWOT ANALYSISOFFERRISCAN
FIG.25 SWOT ANALYSISOFLEICA MICROSYSTEMS
FIG.26 REVENUE BY END MARKETS
FIG.27 SWOT ANALYSISOFLIFE TECHNOLOGIES
Contact Us:
Sona Padman
5320 SW MacadamAvenue,
Suite 100, Portland, OR97239
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555 (U.S. & Canada)
Fax: +1 (855) 550-5975
Email: sales@reportsandintelligence.com
Web: http://www.reportsandintelligence.com/